These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 24511648)

  • 1. Renal safety and angiotensin II blockade medications in patients undergoing non-emergent coronary angiography: a randomized controlled study.
    Wolak T; Aliev E; Rogachev B; Baumfeld Y; Cafri C; Abu-Shakra M; Novack V
    Isr Med Assoc J; 2013 Nov; 15(11):682-7. PubMed ID: 24511648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACE inhibitor or angiotensin II receptor blocker use is a risk factor for contrast-induced nephropathy.
    Umruddin Z; Moe K; Superdock K
    J Nephrol; 2012; 25(5):776-81. PubMed ID: 22322819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
    Onuigbo MA; Onuigbo NT
    QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renin-angiotensin system blockade and contrast-induced renal toxicity.
    Saudan P; Muller H; Feraille E; Martin PY; Mach F
    J Nephrol; 2008; 21(5):681-5. PubMed ID: 18949722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of withdrawing vs continuing renin-angiotensin blockers on incidence of acute kidney injury in patients with renal insufficiency undergoing cardiac catheterization: Results from the Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker and Contrast Induced Nephropathy in Patients Receiving Cardiac Catheterization (CAPTAIN) trial.
    Bainey KR; Rahim S; Etherington K; Rokoss ML; Natarajan MK; Velianou JL; Brons S; Mehta SR;
    Am Heart J; 2015 Jul; 170(1):110-6. PubMed ID: 26093871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy.
    Cirit M; Toprak O; Yesil M; Bayata S; Postaci N; Pupim L; Esi E
    Nephron Clin Pract; 2006; 104(1):c20-7. PubMed ID: 16685140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does renin-angiotensin aldosterone system blockade exacerbate contrast-induced nephropathy in patients with chronic kidney disease? A prospective 50-month Mayo Clinic study.
    Onuigbo MA; Onuigbo NT
    Ren Fail; 2008; 30(1):67-72. PubMed ID: 18197546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or AT-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the Dialysis-versus-Diuresis (DVD) trial.
    Kiski D; Stepper W; Brand E; Breithardt G; Reinecke H
    Nephrol Dial Transplant; 2010 Mar; 25(3):759-64. PubMed ID: 19903660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of renin-angiotensin-aldosterone system blockade on contrast-induced acute kidney injury: a propensity-matched study.
    Rim MY; Ro H; Kang WC; Kim AJ; Park H; Chang JH; Lee HH; Chung W; Jung JY
    Am J Kidney Dis; 2012 Oct; 60(4):576-82. PubMed ID: 22658321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy.
    Rosenstock JL; Bruno R; Kim JK; Lubarsky L; Schaller R; Panagopoulos G; DeVita MV; Michelis MF
    Int Urol Nephrol; 2008; 40(3):749-55. PubMed ID: 18438718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does concurrent renin-angiotensin-aldosterone blockade in (older) chronic kidney disease patients play a role in the acute renal failure epidemic in US hospitalized patients?--Three cases of severe acute renal failure encountered in a northwestern Wisconsin Nephrology practice.
    Onuigbo MA
    Hemodial Int; 2009 Oct; 13 Suppl 1():S24-9. PubMed ID: 19775421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of chronic usage of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on contrast-induced nephropathy in low-risk patients [corrected].
    Barış N; Özpelit E; Doğan NB; Kangül H; Gül S; Akdeniz B; Güneri S
    Anadolu Kardiyol Derg; 2013 May; 13(3):245-50. PubMed ID: 23261803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lower blood vitamin D levels are associated with an increased incidence of contrast-induced nephropathy in patients undergoing coronary angiography.
    Sahin I; Gungor B; Can MM; Avci II; Guler GB; Okuyan E; Biter H; Yildiz SS; Ayca B; Satilmis S; Dinckal MH
    Can J Cardiol; 2014 Apr; 30(4):428-33. PubMed ID: 24680172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.
    Parving HH; Brenner BM; McMurray JJ; de Zeeuw D; Haffner SM; Solomon SD; Chaturvedi N; Ghadanfar M; Weissbach N; Xiang Z; Armbrecht J; Pfeffer MA
    Nephrol Dial Transplant; 2009 May; 24(5):1663-71. PubMed ID: 19145003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of theophylline in preventing contrast-induced nephropathy after coronary angiographic procedures.
    Bilasy ME; Oraby MA; Ismail HM; Maklady FA
    J Interv Cardiol; 2012 Aug; 25(4):404-10. PubMed ID: 22612071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.